Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and Neuropsychiatric Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BRD1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BRD1 Bromodomain Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. Suitable for biophysical assays. |
View BRD1 Products |
| Gene Delivery | BRD1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target validation. |
View BRD1 Products |
| Benchmark Ab | Anti-BRD1 Recombinant Antibody High-affinity positive control for IP, Western Blot, and ChIP assays. |
View BRD1 Products |
| Validator | BRD1 siRNA Set Target-specific knockdown verification to confirm phenotype specificity. |
View BRD1 Products |
| Related Target A | BRPF1 Subfamily member sharing high structural homology; essential for off-target selectivity screening. |
View BRPF1 Products |
| Related Target B | BRPF3 Subfamily member; critical counter-screening partner to ensure molecule specificity. |
View BRPF3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BRPF Subfamily Cross-reactivity | Highly purified BRPF1, BRD1 (BRPF2), and BRPF3 protein panel available for parallel selectivity profiling. |
| Assay Interference from Impurities | Strict endotoxin control (<1 EU/ug) and >95% purity verified by SDS-PAGE to eliminate false positives in HTS. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and siRNA sets included for functional assay calibration. |
| Conformational Stability | Expression in optimized hosts with rigorous quality control to ensure correct folding of the bromodomain pocket. |
Live BRD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BRD1 therapeutics is intensifying, with major players shifting focus from broad-spectrum epigenetic regulators to highly selective BRPF-family bromodomain inhibitors and PROTACs. As first-generation pan-bromodomain inhibitors face toxicity hurdles, the next wave of R&D is targeting tissue-specific BRD1 complexes to address neuropsychiatric disorders and specific hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | GlaxoSmithKline, Bayer, Academic Consortia | Schizophrenia, Bipolar Disorder, AML | High-throughput binding assays (Need sequence-verified, active-site intact BRD1 protein) |
| PROTACs / Degraders | Arvinas, C4 Therapeutics, Yale University | Solid Tumors, Inflammatory Diseases | Ternary complex formation assays (Need high-purity BRD1 and E3 ligase proteins) |
| Combination Therapies | Oncology Biotechs | Refractory Leukemias | Synergistic pathway profiling (Need validated siRNA and pathway-related targets) |